These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
4. Antibody-based therapeutics: focus on prostate cancer. Ross JS; Gray KE; Webb IJ; Gray GS; Rolfe M; Schenkein DP; Nanus DM; Millowsky MI; Bander NH Cancer Metastasis Rev; 2005 Dec; 24(4):521-37. PubMed ID: 16408160 [TBL] [Abstract][Full Text] [Related]
5. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Baxevanis CN; Perez SA; Papamichail M Cancer Immunol Immunother; 2009 Mar; 58(3):317-24. PubMed ID: 18704409 [TBL] [Abstract][Full Text] [Related]
6. Bispecific antibodies for dual-modality cancer therapy: killing two signaling cascades with one stone. Marvin JS; Zhu Z Curr Opin Drug Discov Devel; 2006 Mar; 9(2):184-93. PubMed ID: 16566289 [TBL] [Abstract][Full Text] [Related]
11. New directions in MS therapeutics: vehicles of hope. Fox RJ; Ransohoff RM Trends Immunol; 2004 Dec; 25(12):632-6. PubMed ID: 15530830 [TBL] [Abstract][Full Text] [Related]
12. Antibody production: polyclonal-derived biotherapeutics. Newcombe C; Newcombe AR J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Mar; 848(1):2-7. PubMed ID: 16893686 [TBL] [Abstract][Full Text] [Related]
13. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones. Workman P Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933 [TBL] [Abstract][Full Text] [Related]
14. Molecular biological assessment methods and understanding the course of the HIV infection. Katzenstein TL APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050 [TBL] [Abstract][Full Text] [Related]
16. Biological Therapy of Cancer--fifth symposium. From basic research to clinical application. 27-30 October 1999, Munich, Germany. Francis R; Chao D IDrugs; 2000 Feb; 3(2):142-6. PubMed ID: 16107923 [TBL] [Abstract][Full Text] [Related]
17. The use of antibodies in the treatment of infectious diseases. Chan CE; Chan AH; Hanson BJ; Ooi EE Singapore Med J; 2009 Jul; 50(7):663-72; quiz 673. PubMed ID: 19644620 [TBL] [Abstract][Full Text] [Related]
18. New approaches to antibody therapy. Weiner LM; Adams GP Oncogene; 2000 Dec; 19(53):6144-51. PubMed ID: 11156528 [TBL] [Abstract][Full Text] [Related]
19. Antibody-based immunotherapy in high-risk neuroblastoma. Johnson E; Dean SM; Sondel PM Expert Rev Mol Med; 2007 Dec; 9(34):1-21. PubMed ID: 18081947 [TBL] [Abstract][Full Text] [Related]
20. Engineered antibodies take center stage. Huston JS; George AJ Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]